Previous 10 | Next 10 |
As I covered earlier this month , the companies implicated in the opioid epidemic in a recent exposé by the Washington Post are in dire straits. My thesis in that article was that any settlement would be symbolic because the companies cannot afford big payouts. Teva ( TEVA ), McKesson ...
Company Thesis ANI Pharmaceuticals' ( ANIP ) cortrophin will likely be the sole generic competitor to Mallinckrodt's ( MNK ) blockbuster H.P. Acthar Gel, besting Assertio Therapeutic s' ( ASRT ) investigative cosyntrophin by a wide margin. The company's 5 key branded launches in the past fis...
LAKE FOREST, Ill., July 17, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets. Following the announcement, the Company will host a conference ...
Introduction Assertio Therapeutics ( ASRT ) is a specialty pharmaceuticals company which successfully divested itself of its painkiller exposure in response to the opioid crisis. Despite turnaround efforts such as a settlement with Purdue, cutting most of its sales force, and NDA for cosyn...
Start Time: 16:30 End Time: 17:00 Assertio Therapeutics, Inc. (ASRT) Q1 2019 Earnings Conference Call May 08, 2019, 16:30 PM ET Company Participants Arthur Higgins - President and CEO Dan Peisert - SVP and CFO John Thomas - SVP, IR and Corporate Communications Conference C...
The following slide deck was published by Assertio Therapeutics, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Assertio Therapeutics (NASDAQ: ASRT ): Q1 Non-GAAP EPS of $0.23 beats by $0.05 ; GAAP EPS of -$0.22 beats by $0.05 . More news on: Assertio Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance -- -- Significant Debt Reduction -- LAKE FOREST, Ill., May 08,...
Assertio Therapeutics (NASDAQ: ASRT ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after market close. The consensus EPS Estimate is $0.18 (-35.7% Y/Y) and the consensus Revenue Estimate is $55.28M (-12.9% Y/Y). Over the last 2 years, asrt has beaten EPS estimat...
LAKE FOREST, Ill., April 24, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of markets. Following the announcement, the Company will host a conference cal...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...